A case of common variable immune deficiency with lung disease–not just bronchiectasis
Abstract
Introduction: Common Variable Immune Deficiency (CVID) is the most prevalent form of severe antibody deficiency in children and adults. Most patients suffer recurrent, mainly sinopulmonary, infections. Despite adequate IVIG replacement therapy, chronic lung disease continues to be a main cause of morbidity and mortality. The term granulomatous-lymphocytic interstitial lung disease (GLILD) is frequently used to describe interstitial lung disease associated with immune dysregulation in primary antibody deficiency, such as CVID.
Aim: To describe the case of a 10-year-old male with CVID who developed GLILD and his response to treatment with Rituximab.
Discussion: Our patient is a young male with CVID and no genetic diagnosis, whose lung functions and general condition continued to deteriorate despite adequate intravenous immunoglobulin replacement therapy and mycophenolate mofetil treatment. After the diagnosis of GLILD, we initiated treatment with a 4-dose weekly course of Rituximab with prompt resolution of his interstitial disease. Although GLILD is a well described condition that accompanies CVID as a manifestation of immune dysregulation, it is still under recognized, especially in the pediatric population. Among experts, there is little uniformity when it comes to diagnostic and treatment approaches. Recent studies showed improved outcomes when using combination therapy with Rituximab, such as in our patient.
Statement of Novelty: We shed light on GLILD, an important condition that accompanies CVID, and demonstrate an excellent response to the steroid sparing agent Rituximab. This is a crucial aspect when considering therapeutic choices for the pediatric population.
Formats available
You can view the full content in the following formats:
REFERENCES
Baumann U., Routes J.M., Soler-Palacín P., and Jolles S. 2018. The lung in primary immunodeficiencies: New concepts in infection and inflammation. Front. Immunol. 9: 1837.
Bousfiha A., Jeddane L., Picard C., Al-Herz W., Ailal F., Chatila T., Cunningham-Rundles C., Etzioni A., Franco J.L., Holland S.M., Klein C., Morio T., Ochs H.D., Oksenhendler E., Puck J., Torgerson T.R., Casanova J.L., Sullivan K.E., and Tangye S.G. 2020. Human inborn errors of immunity: 2019 Update of the IUIS phenotypical classification. J. Clin. Immunol. 40(1): 66–81.
Hurst J.R., Verma N., Lowe D., Baxendale H.E., Jolles S., Kelleher P., Longhurst H.J., Patel S.Y., Renzoni E.A., Sander C.R., Avery G.R., Babar J.L., Buckland M.S., Burns S., Egner W., Gompels M.M., Gordins P., Haddock J.A., Hart S.P., Hayman G.R., Herriot R., Hoyles R.K., Huissoon A.P., Jacob J., Nicholson A.G., Rassl D.M., Sargur R.B., Savic S., Seneviratne S.L., Sheaff M., Vaitla V.P.M., Walters G.I., Whitehouse J.L., Wright P.A., and Condliffe A.M. 2017. British lung foundation/united kingdom primary immunodeficiency network consensus statement on the definition, diagnosis, and management of GLILD in CVID. J. Allergy Clin. Immunol. Pract. 5(4): 938–945.
Maglione P.J. 2020. Chronic lung disease in primary antibody deficiency: Diagnosis and management. Immunol. Allergy Clin. North Am. 40(2): 437–459.
van de Ven A.A.J.M., Alfaro T.M., Robinson A., Baumann U., Bergeron A., Burns S.O., Condliffe A.M., Fevang B., Gennery A.R., Haerynck F., Jacob J., Jolles S., Malphettes M., Meignin V., Milota T., van Montfrans J., Prasse A., Quinti I., Renzoni E., Stolz D., Warnatz K., and Hurst J.R. 2020. Managing granulomatous-lymphocytic interstitial lung disease in common variable immunodeficiency disorders: E-glildnet international clinicians survey. Front Immunol. 11: 606333.
Verbsky J.W., Hintermeyer M.K., Simpson P.M., Feng M., Barbeau J., Rao N., Cool C.D., Sosa-Lozano L.A., Baruah D., Hammelev E., Busalacchi A., Rymaszewski A., Woodliff J., Chen S., Bausch-Jurken M., and Routes J.M. 2021. Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency. J. Allergy Clin. Immunol. 147(2): 704–712.e17.
Information & Authors
Information
Published In
LymphoSign Journal
Volume 8 • Number 3 • September 2021
Pages: 81 - 85
History
Received: 22 August 2021
Accepted: 30 August 2021
Accepted manuscript online: 30 August 2021
Copyright
© 2021.
Authors
Metrics & Citations
Metrics
Other Metrics
Citations
Cite As
SharonPolakow Farkash, ShaiEhrlich, GuySteuer, JoanneYacobovich, NirDiamant, and NufarMarcus. 2021. A case of common variable immune deficiency with lung disease–not just bronchiectasis. LymphoSign Journal.
8(3): 81-85. https://doi.org/10.14785/lymphosign-2021-0026
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
There are no citations for this item
View Options
Get Access
Login options
Check if you access through your login credentials or your institution to get full access on this article.
